[vc_row][vc_column]
Developing drugs for rare diseases, once a rare phenomenon itself, has now become a standard strategy for many companies’ drug development pipelines<\/p>\n
[\/vc_column_text][\/vc_column_inner][vc_column_inner width=”2\/3″ css=”.vc_custom_1706533013753{margin-left: 4% !important;}”]
<\/i> Top 10 Selling Orphan Drugs<\/a>[\/vc_column_text] Bringing medical technology products to market is typically a time-consuming task. The journey involves navigating two distinct phases: pre-approval and post-approval<\/p>\n [\/vc_column_text][\/vc_column_inner][vc_column_inner width=”2\/3″ css=”.vc_custom_1706533013753{margin-left: 4% !important;}”] <\/i> Med Tech Approval and Launch Process in US<\/a>[\/vc_column_text] This involves engaging with a diverse set of stakeholders, most prominently payers, who play a crucial role in determining which drugs make it to the market<\/p>\n [\/vc_column_text][\/vc_column_inner][vc_column_inner width=”2\/3″ css=”.vc_custom_1706533013753{margin-left: 4% !important;}”] <\/i> Market Access Process in Pharma Product Launch<\/a><\/p>\n <\/i> Pharmacy Benefit Manager (PBM): An Important Stakeholder in US Healthcare System<\/a>[\/vc_column_text] Competitive intelligence serves as a key tool for pharmaceutical companies, providing valuable insights into their market, competitors, and customers, thereby enabling more effective decision-making<\/p>\n [\/vc_column_text][\/vc_column_inner][vc_column_inner width=”2\/3″ css=”.vc_custom_1706533013753{margin-left: 4% !important;}”] <\/i> Competitive Intelligence and its Importance in Pharma<\/a>[\/vc_column_text] Medical affairs team gathers insights from essential stakeholders such as patients, HCPs, and payers, covering aspects of the patient journey, treatment landscape, products, and regulatory and reimbursement considerations<\/p>\n [\/vc_column_text][\/vc_column_inner][vc_column_inner width=”2\/3″ css=”.vc_custom_1706533013753{margin-left: 4% !important;}”] <\/i> Advisory Board: Roles & Responsibilities<\/a><\/p>\n <\/i> Real world evidences (RWEs): Importance for Pharma <\/a>[\/vc_column_text] HEOR assists healthcare decision-makers, including clinicians, governments, payers, health authorities, and patients, among others, in comparing the benefits and costs of available interventions and selecting from among these options<\/p>\n [\/vc_column_text][\/vc_column_inner][vc_column_inner width=”2\/3″ css=”.vc_custom_1706533013753{margin-left: 4% !important;}”] <\/i> Country HTA Snapshots: Germany, France, UK<\/a><\/p>\n <\/i> Country HTA Snapshots: Australia, Japan, South Korea, and Taiwan<\/a>[\/vc_column_text] Pharmaceutical forecasting takes into account a multitude of market factors, such as patient access, clinical development, competitor activity, payer dynamics, product launch timings, product life cycle stage, RoA and dosage, promotions, and pricing strategy<\/p>\n [\/vc_column_text][\/vc_column_inner][vc_column_inner width=”2\/3″ css=”.vc_custom_1706533013753{margin-left: 4% !important;}”] PMR involves gathering data directly from target audiences, such as healthcare professionals, patients, payers, and other stakeholders. This research aims to understand their preferences, needs, behaviors, and perceptions regarding the products and services<\/p>\n [\/vc_column_text][\/vc_column_inner][vc_column_inner width=”2\/3″ css=”.vc_custom_1706533013753{margin-left: 4% !important;}”]Med Tech<\/h1>\n
Market Access<\/h1>\n
Competitive Intelligence<\/h1>\n
Medical Affairs<\/h1>\n
HEOR<\/h1>\n
Forecasting<\/h1>\n
Primary Market Research<\/h1>\n